Note: Single-source report; awaiting corroboration.
The NIH has announced the development of an artificial intelligence (AI) algorithm designed to match potential volunteers with clinical trials based on eligibility criteria. This tool may help clinicians save time in the matching process and could accelerate the enrollment phase of clinical research.
The AI algorithm is part of broader NIH clinical research efforts across various diseases. For example, NIH has recently initiated clinical trials on a rectal microbicide as a potential HIV prevention method and launched a precision medicine treatment trial for myeloid cancers such as acute myeloid leukemia and myelodysplastic syndromes.
NIH-supported studies have also investigated combining JAK inhibitors with immune checkpoint inhibitors in cancer, the safety of vigorous exercise in genetic heart conditions, and novel immunotherapy for metastatic solid tumors. Experimental approaches, such as nanoparticle-based mRNA vaccines, are being explored for brain cancers including glioblastoma.
These advances reflect NIH's ongoing strategy of using innovative technologies and treatments, including immunotherapy and precision medicine, backed by clinical trials to improve outcomes across various conditions.